Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
Elevai Labs, Inc. (NASDAQ: ELAB) has announced promising results from an ongoing research study on hair restoration using their proprietary Elevai Exosomes™ technology. The study, conducted in partnership with the National Hair Loss Medical Aesthetics (NHLMA), demonstrated potential benefits for individuals experiencing hair loss or thinning.
Key findings include:
- Ceased crown inflammation
- Reversal of miniaturized hairs
- Recovery of dormant hair
The treatment involved scalp microneedling with Elevai empower™ in-office, followed by at-home use of Elevai enfinity™. Elevai is now conducting further research on their new S-Series Root Renewal System™, which combines exosome and mitochondrial technology for enhanced scalp and hair vitality.
Elevai Labs, Inc. (NASDAQ: ELAB) ha annunciato risultati promettenti da uno studio di ricerca in corso sulla restauraione dei capelli utilizzando la loro tecnologia proprietaria Elevai Exosomes™. Lo studio, condotto in collaborazione con il National Hair Loss Medical Aesthetics (NHLMA), ha dimostrato potenziali benefici per le persone che sperimentano perdita o diradamento dei capelli.
I principali risultati includono:
- Interruzione dell'infiammazione al cuoio capelluto
- Ripristino dei capelli miniaturizzati
- Recupero dei capelli dormienti
Il trattamento ha contemplato la microneedling del cuoio capelluto con Elevai empower™ in ufficio, seguito dall'uso domestico di Elevai enfinity™. Elevai sta ora conducendo ulteriori ricerche sul loro nuovo S-Series Root Renewal System™, che combina tecnologia a base di esosomi e mitocondri per una maggiore vitalità del cuoio capelluto e dei capelli.
Elevai Labs, Inc. (NASDAQ: ELAB) ha anunciado resultados prometedores de un estudio de investigación en curso sobre la restauración del cabello utilizando su tecnología patentada Elevai Exosomes™. El estudio, realizado en asociación con el National Hair Loss Medical Aesthetics (NHLMA), demostró beneficios potenciales para las personas que experimentan pérdida o adelgazamiento del cabello.
Los hallazgos clave incluyen:
- Cesación de la inflamación en la coronilla
- Reversión de los cabellos miniaturizados
- Recuperación del cabello inactivo
El tratamiento involucró microneedling del cuero cabelludo con Elevai empower™ en la consulta, seguido por el uso en casa de Elevai enfinity™. Elevai ahora está llevando a cabo más investigaciones sobre su nuevo S-Series Root Renewal System™, que combina tecnología de exosomas y mitocondrias para mejorar la vitalidad del cuero cabelludo y el cabello.
Elevai Labs, Inc.(NASDAQ: ELAB)는 자사의 독점 기술 Elevai Exosomes™를 사용한 모발 복원 연구에서 유망한 결과를 발표했습니다. 이 연구는 National Hair Loss Medical Aesthetics(NHLMA)와 협력하여 진행되었으며, 탈모나 모발이 얇아지는 경험을 하는 개인들에게 잠재적인 혜택을 보여주었습니다.
주요 발견은 다음과 같습니다:
- 정수리 염증 완화
- 미세화된 모발의 역전
- 휴면 모발 회복
치료는 Elevai empower™를 사용한 두피 마이크로니들링과 후속으로 Elevai enfinity™의 가정용 사용이 포함되었습니다. Elevai는 이제 S-Series Root Renewal System™에 대한 추가 연구를 진행 중이며, 이는 두피와 모발의 활력을 높이기 위해 엑소좀 및 미토콘드리아 기술을 결합한 것입니다.
Elevai Labs, Inc. (NASDAQ: ELAB) a annoncé des résultats prometteurs d'une étude de recherche en cours sur la restauration des cheveux utilisant leur technologie propriétaire Elevai Exosomes™. L'étude, réalisée en partenariat avec le National Hair Loss Medical Aesthetics (NHLMA), a démontré des avantages potentiels pour les individus souffrant de perte de cheveux ou d'amincissement.
Les résultats clés incluent :
- Fin de l'inflammation du cuir chevelu
- Inversion des cheveux miniaturisés
- Récupération des cheveux dormants
Le traitement a impliqué un microneedling du cuir chevelu avec Elevai empower™ en cabinet, suivi de l'utilisation à domicile de Elevai enfinity™. Elevai mène maintenant des recherches supplémentaires sur leur nouveau S-Series Root Renewal System™, qui combine la technologie des exosomes et des mitochondries pour améliorer la vitalité du cuir chevelu et des cheveux.
Elevai Labs, Inc. (NASDAQ: ELAB) hat vielversprechende Ergebnisse aus einer laufenden Forschungsstudie zur Haarrestaurierung mit ihrer proprietären Technologie Elevai Exosomes™ bekannt gegeben. Die Studie, die in Zusammenarbeit mit den National Hair Loss Medical Aesthetics (NHLMA) durchgeführt wurde, zeigte potenzielle Vorteile für Personen, die unter Haarausfall oder dünner werdendem Haar leiden.
Zu den wichtigsten Ergebnissen gehören:
- Gestoppte Entzündung der Kopfhaut
- Rückkehr von miniaturisierten Haaren
- Erholung von schlafenden Haaren
Die Behandlung umfasste die Mikronadelung der Kopfhaut mit Elevai empower™ in der Praxis, gefolgt von der häuslichen Anwendung von Elevai enfinity™. Elevai führt jetzt weitere Forschungen zu ihrem neuen S-Series Root Renewal System™ durch, das Exosomen- und Mitochondrientechnologie zur Verbesserung der Vitalität von Kopfhaut und Haaren kombiniert.
- Promising results in hair restoration study using proprietary Elevai Exosomes™ technology
- Demonstrated benefits include ceased crown inflammation and reversal of miniaturized hairs
- Ongoing research on new S-Series Root Renewal System™ combining exosome and mitochondrial technology
- None.
The preliminary results from Elevai's hair restoration study are encouraging but require cautious interpretation. The combination of microneedling and exosome application shows promise in addressing androgenetic alopecia, with reported benefits including reduced inflammation and reversal of hair miniaturization. However, it's important to note that this is an ongoing study without peer-reviewed publication yet.
The dual-mechanism approach, combining exosomes and mitochondrial technology, is innovative and could potentially address multiple aspects of hair loss. However, the efficacy and safety of this combination need rigorous testing. The transition from preliminary results to a marketable product line (Elevai S-Series Root Renewal System™) seems rapid, raising questions about the depth of clinical validation.
Investors should be aware that the hair restoration market is highly competitive and regulated. While Elevai's approach is promising, it's essential to await more comprehensive, long-term data before drawing definitive conclusions about its market potential.
Elevai's venture into the hair restoration market represents a significant diversification of their product portfolio. The global hair restoration market was valued at
The company's partnership with NHLMA lends credibility to their research and could facilitate faster market penetration. However, the hair restoration field is crowded with established players and numerous treatment options. Elevai will need to demonstrate clear superiority or unique benefits to carve out a significant market share.
The dual-technology approach (exosomes and mitochondrial) could be a key differentiator if proven effective. This unique selling proposition could appeal to both clinicians and consumers seeking innovative solutions. However, the success will heavily depend on the final clinical outcomes and the company's ability to effectively market and distribute the product line.
- On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™.
- Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality.
NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hair Loss Medical Aesthetics (“NHLMA”), demonstrating the potential of its proprietary Elevai Exosomes™ in hair restoration.
The research study assessed the application of topical Elevai exosomes, in clinic and at home, on participants experiencing hair loss or hair thinning. Study participants were given in-office treatment consisting of scalp microneedling, then Elevai empower™, a topical exosome serum designed specifically for in-office application was applied, followed by at-home use of Elevai enfinity™, a topical exosome product, on the areas of concern. Results were assessed using imaging analysis up to 12 months, showing ceased crown inflammation, reversal of miniaturized hairs and recovered hair from the dormant phase, among other benefits.
“We tested patients with androgenetic alopecia, delivering Elevai’s unique age zero exosomes to the scalp focusing on areas of thinning”, said Carly Klein, President of NHLMA. “These exosomes were utilized in the early and late stages of hair loss, and we saw promising results, giving us confidence that this technology can be used successfully in combination with other hair restoration approaches.”
This study is a precursor to ongoing research that Elevai is conducting on the new hair and scalp care product line, Elevai S-Series Root Renewal SystemTM. The Elevai S-Series product line is a three-part hair and scalp care system that utilizes a first-in-class dual mechanism powered by exosomes and mitochondrial technology that incorporates Elevai’s proprietary PREx™ and Yuva Bioscience’s Y100 mitochondrial technology.
“NHLMA’s findings provide the initial validation of our exosome technology on hair and scalp health,” stated Dr. Jordan R. Plews, PhD, the Chief Executive Officer of Elevai Skincare Inc. “We are in the process of conducting a follow-on study with the combination of Elevai exosomes and Yuva’s Y100 mitochondrial technology to address common scalp and hair care concerns, such as the appearance of thinning hair, by promoting scalp and hair vitality.”
About Elevai Labs Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Skincare Inc.
Elevai Skincare Inc., a subsidiary of Elevai Labs Inc., is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications. Elevai Skincare Inc. develops cosmetic products for the physician-dispensed market, with a focus on leveraging novel proprietary science-backed technologies, including its stem cell exosome technology. For more information, please visit www.elevaiskincare.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai’s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies.
These and other risks are described more fully in Elevai Labs’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Makenzie Mann
contact@elevailabs.com
FAQ
What are the key findings of Elevai Labs' hair restoration study using Elevai Exosomes™?
How was the Elevai Exosomes™ treatment applied in the hair restoration study?
What is Elevai Labs (ELAB) currently researching for hair and scalp care?
Who partnered with Elevai Labs (ELAB) for the hair restoration study?
